A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic
Explore this paper's citation graph
Summary
The role of liquid biopsy in managing lung cancer patients during the still ongoing coronavirus disease 2019 (COVID-19) healthcare emergency is evaluated and may represent a valid and less time-consuming diagnostic approach than conventional tissue and cytological specimens.
- Type
- review
- Published
- 2021-01-01
- Cited by
- 14
- References
- 81
- Access
- Open access
- OpenAlex
- https://openalex.org/W3186687867
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:237698118
Keywords
Pandemic, Medicine, Liquid biopsy, Intensive care medicine, Coronavirus disease 2019 (COVID-19)
References
- An integrated semiconductor device enabling non-optical genome sequencing
- Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry
- EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study
- Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
- Evaluation of a novel saliva‐based epidermal growth factor receptor mutation detection for lung cancer: A pilot study
- Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
- Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
- Integrating liquid biopsies into the management of cancer
- Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer
- Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting.
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
- Liquid biopsy for early stage lung cancer.
- Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
- EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
- Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
- Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
Cited by
- Recent Advances in Liquid Biopsy of Brain Cancers
- The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
- Navigating the liquid biopsy Minimal Residual Disease (MRD) in Non-Small Cell Lung Cancer: Making the Invisible Visible.
- Salivary miRNA Profiles in COVID-19 Patients with Different Disease Severities
- The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?
- Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”
- Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer
- Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer
- Oncogenic potential of SARS-CoV-2—targeting hallmarks of cancer pathways
- Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients
- Liquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions
- Smaller, cheaper, faster: where next for liquid biopsies?
- Editorial: Real-world data and real-world evidence in lung cancer
Related papers
- Pediatricians Face Challenges in Diagnosing Post-COVID-19 Conditions (Long COVID)
- Urine-Based Liquid Biopsy for Nonurological Cancers
- What if the worst consequences of COVID-19 concerned non-COVID patients?
- ХАРАКТЕРИСТИКА ОЧАГОВ COVID-19 С РАСПРОСТРАНЕНИЕМ В ОРГАНИЗОВАННЫХ КОЛЛЕКТИВАХ, ЗАРЕГИСТРИРОВАННЫХ В ХАБАРОВСКОМ КРАЕ В ПЕРИОД С АПРЕЛЯ ПО СЕНТЯБРЬ 2020 Г.
- The Role of Liquid Biopsy in the Diagnosis and Prognosis of WHO Grade 4 Astrocytoma
- Surviving through the COVID-19 pandemic!
- Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions.
- Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer
- 910P Assessment of early detection by multi-omics-based liquid biopsy in lung cancer: A prospective study (ASCEND-LUNG)